March 1st, 2011
Announcing 510(k) Clearance of a New Microfluidic-based IVD Test System, the μTASWakoTM i30 Immunoanalyzer, and AFP-L3 and DCP Assays for Liver Cancer Risk Assessment.
Contact: Audrey Long at 877-714-1924
Oct. 2010
New! Quest Diagnostics now offers HCC panel test. This HCC panel test conveniently allows measurement of AFP-L3% and DCP with a single test code: 16222
Clinical Diagnostic Reagents:
diagnostics@wakousa.com
HCC Biomarkers and
μTASWako® i30:
liver@wakousa.com
Phone: 877-714-1924
ISO 13485:2003
Wako is a comprehensive manufacturer of Clinical Diagnostic reagents that are of the highest quality and good value to performance. Our products are the result of nearly 90 years of dedication to the field of in vitro diagnostics.
FDA 510(k) Cleared
for HCC Risk Assessment
Wako's AFP-L3 and DCP (also known as PIVKA-II) tests are available through major reference labs.
To learn how HCC biomarkers can improve surveillance of HCC:
DDW 2012
Digestive Disease Week
May 19-22, 2012
San Diego, CA
Booth #2931
Please visit the presentation at
DDW Theater
2:00 PM, Sunday, May 20th
"Up To Date Screening for Hepatocellular Carcinoma:
Adding AFP-L3 and DCP Biomarkers"
By Catherine T. Frenette, M.D.
Medical Director of Liver Transplantation and Hepatocellular Carcinoma Program
The Methodist Hospital, Houston, TX
Clinical Lab Expo 2012
AACC, American Association of Clinical Chemistry
July 15-19, 2012
Los Angeles, CA
Booth #1617
ACG 2012
American College of Gastroenterology
Oct 19-24, 2012
Las Vegas, NV
Booth TBD
TLM 2012
The Liver Meeting
Nov 1-5, 2012
Boston, MA
Booth TBD